quarta-feira, 7 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 14, 2026

Big Investing Takeaways From CES 2026

View original at nasdaq.com
Big Investing Takeaways From CES 2026 In this podcast, Motley Fool contributors Travis Hoium, Lou Whiteman, and Rachel Warren discuss: Uber and Lucid's big reveal.Nvidia's autonomy model.Lego's smart blocks.Duds at CES…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Nvidia recommendation on April 15, 2005 would have turned $1,000 into $1,133,548

    80% confidence
  • We need to remain excited about autonomous vehicles because there's a ton of CAPEX and high costs

    80% confidence
  • Lucid vehicles are expensive automobiles with $80,000 plus retail price, making the robotaxi economics questionable compared to vehicles with more economies of scale

    80% confidence
  • The Uber-Lucid-Nuro partnership could create blueprint for specialized horizontal partnership model rather than vertical integration seen with Waymo

    80% confidence
  • Challenges whether there's a fundamental business model behind many AI products being demonstrated at CES if GPUs are being used to build products like AI soulmates that people won't actually buy

    80% confidence
  • Netflix recommendation on December 17, 2004 would have turned $1,000 into $482,209

    80% confidence
  • Looking at CES 2026, we may be at a point on technological curve where it's hard to come up with something that really moves the needle - perhaps we're being too hard on Apple for not coming up with next big thing

    80% confidence
  • Lenovo smart glasses didn't offer any compelling use cases compared to Meta's smart glasses

    80% confidence
  • Stock Advisor total average return is 968% compared to 197% for S&P 500

    80% confidence
  • Smart blocks represent the most significant evolution in their products since 1978 minifigure

    80% confidence
  • Smart blocks feel like 'just because you can' rather than something kids will really care about or drive revenue

    80% confidence
  • Once autonomous systems reach critical mass of reliability, only engineers and fanboys will care about technological superiority - investing billions for marginal improvement may not be money well spent

    80% confidence
  • Lego's most significant evolution was probably when they started marketing $500 sets for adults with creator's editions, which will be more of a revenue driver than smart blocks

    80% confidence
  • If horizontal partnership model works, it could be replicated with every single OEM partnering with companies like Mobileye

    80% confidence
  • Commercial autonomous robotaxi service planned for late 2026 in Bay Area

    80% confidence
  • Best strategy in autonomy for automakers may have been to wait and see who can figure it out rather than investing billions themselves

    80% confidence
  • Plans to deploy about 20,000 or more autonomous vehicles over next six years across dozens of global markets

    80% confidence
  • AMI AI soulmate is an example of putting AI into products that don't need it

    80% confidence
  • LG Cloudroid home robot was creepy with weird figure

    80% confidence
  • Analyst team identified 10 best stocks to buy now and Nvidia wasn't one of them

    80% confidence

Citado nestas reportagens da Via News

O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,986
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,986 factos verificados com a fonte5,362 documentos-fonte arquivados
Consulte estes dados → isubstrate.com